Introduction: Childhood obesity is among the most serious and rapidly growing public health issues globally. Although body mass index (BMI) is commonly used to evaluate obesity, it does not always reflect early metabolic disturbances. Recent studies have emphasized the importance of metabolomics, particularly plasma amino acid profiling, in detecting subclinical metabolic risk. In this context, branched-chain amino acids (BCAAs) have emerged as potential early biomarkers of insulin resistance and cardiometabolic risk.Methods: This cross-sectional study included 97 participants aged 5–18 years, including 56 children with obesity (BMI ≥ 95th percentile) and 41 healthy controls. Anthropometric measurements, as well as fasting glucose, insulin, lipid profile, and HbA1c levels, were recorded. Plasma concentrations of 44 amino acids were measured using liquid chromatography–tandem mass spectrometry (LC–MS/MS) with a commercial kit (JASEM®, Agilent Ultivo Triple Quadrupole LC–MS). BCAA levels and relevant ratios, such as glycine/BCAA and glutamic acid/glutamine, were calculated. Receiver operating characteristic (ROC) curve analyses were performed to evaluate the diagnostic performance of key variables.Results: Children with obesity had significantly higher levels of BCAAs and other amino acids, including phenylalanine, tyrosine, alanine, and glutamic acid (all p < 0.05). Conversely, glycine, serine, and asparagine levels were significantly lower in children with obesity. Fasting insulin emerged as a strong predictor of obesity [area under the ROC curve (AUC) = 0.87], while total BCAAs also displayed strong predictive performance (AUC = 0.78). A reduced glycine/BCAA ratio and an increased glutamic acid/glutamine ratio were associated with early metabolic dysregulation.Conclusion: Our findings highlight the potential of plasma amino acid profiling as a supportive tool for the early assessment of metabolic risk in children with obesity. The integration of amino acid-based indices could improve risk classification and support personalized preventive strategies in pediatric populations.
Congenital sphingosine-1-phosphate (S1P) lyase deficiency due to biallelic mutations in SGPL1 gene has recently been described in association with primary adrenal insufficiency and steroid-resistant nephrotic syndrome. S1P lyase, on the other hand, is therapeutically inhibited by fingolimod which is an oral drug for relapsing multiple sclerosis (MS). Effects of this treatment on adrenal function has not yet been evaluated. We aimed to test adrenal function of MS patients receiving long-term fingolimod treatment. Nineteen patients (14 women) with MS receiving oral fingolimod (Gilenya®, Novartis) therapy were included. Median age was 34.2 years (range; 21.3–44.6 years). Median duration of fingolimod treatment was 32 months (range; 6–52 months) at a dose of 0.5 mg/day. Basal and ACTH-stimulated adrenal steroid measurements were evaluated simultaneously employing LC-MS/MS based steroid panel. Basal steroid concentrations were also compared to that of sex- and age-matched healthy subjects. Cortisol and 11-deoxycortisol, 11-deoxycorticosterone and dehydroepiandrosterone were used to assess glucocorticoid, mineralocorticoid and sex steroid producing pathways, respectively. Basal ACTH concentrations of the patients were 20.8 pg/mL (6.8–37.8 pg/mL) (normal range; 5–65 pg/mL). There was no significant difference in the basal concentrations of cortisol, 11-deoxycortisol, 11-deoxycorticosterone and dehydroepiandrosterone between patients and controls (p = 0.11, 0.058, 0.74, 0.15; respectively). All patients showed adequate cortisol response to 250 mcg IV ACTH stimulation (243 ng/mL, range; 197–362 ng/mL). There was no significant correlation between duration of fingolimod treatment and basal or ACTH-stimulated cortisol or change in cortisol concentrations during ACTH stimulation test (p = 0.57, 0.66 and 0.21, respectively). Modification and inhibition of S1P lyase activity by the long-term therapeutic use of fingolimod is not associated with adrenal insufficiency in adult patients with MS. This suggests that S1P lyase has potentially a critical role on adrenal development rather than the function of a fully mature adrenal gland.